Millions of people worldwide suffer from chronic and incurable inflammatory diseases such as inflammatory bowel disease, vasculitis and lupus.
Immune-mediated inflammatory diseases are all heterogeneous, with highly variable clinical outcomes. Historically, there has been no way of predicting at diagnosis whether a patient is likely to experience a refractory, relapsing form of the disease or follow a more quiescent course requiring less treatment.
Our current test stratifies IBD patients into two groups; those at high-risk of severe relapsing disease, and those more likely to experience a less aggressive disease course. These distinct disease phenotypes may benefit from different treatment pathways. Whilst our technology focusses on a single disease at present, we hope to extend its use to address other immune-mediated inflammatory diseases in the future.